Analysis of the impact of immunotherapy efficacy and safety in patients with gastric cancer and liver metastasis

Table 1 Comparison of clinical features of gastric cancer patients, n (%)

Clinical features	Hepatic metastases (n = 20)	No hepatic metastases (n = 28)	χ2	P value
Age in yr
< 65	4 (20.0)	11 (39.3)	2.020	0.212
≥ 65	16 (80.0)	17 (60.7)
Gender
Male	13 (65.0)	18 (64.3)	0.003	0.999
Female	7 (35.0)	10 (35.7)
ECOG score
0	6 (30.0)	5 (17.8)	9.116	0.011
1	8 (40.0)	22 (78.6)
2	6 (30.0)	1 (3.6)
Histological type
Adenocarcinoma	19 (95.0)	27 (96.4)	2.117	0.347
Signet-ring cell carcinoma	0 (0.0)	1 (3.6)
Unknown	1 (5.0)	0 (0.0)
PD-L1 expression
≥ 1%	9 (45.0)	11 (39.3)	0.206	0.902
< 1%	10 (50.0)	15 (53.6)
Unknown	1 (5.0)	2 (7.1)
Number of treatment lines
1	11 (55.0)	14 (50.0)	2.672	0.263
2	8 (40.0)	8 (28.6)
≥ 3	1 (5.0)	6 (21.4)
Treatment plan
Chemotherapy + immunotherapy	19 (95.0)	26 (92.8)	0.777	0.658
Antiangiogenic therapy + immunotherapy	1 (5.0)	1 (3.6)
Immunotherapy	0 (0.0)	1 (3.6)

PD-L1: Programmed cell death ligand 1.

Table 2 Comparison of adverse reactions of immunotherapy in patients with advanced gastric cancer with liver metastasis and no liver metastasis grade 1-2, n (%)

Adverse reaction	Liver metastasis (n = 20)	No liver metastasis grade 1-2 (n = 28)	χ2	P value
All events related to treatment	10 (50.0)	13 (46.4)	0.060	0.999
Nausea	7 (35.0)	7 (25.0)	0.565	0.528
Diarrhea	6 (30.0)	8 (29.0)	0.012	0.999
Fever	5 (25.0)	8 (29.0)	0.075	0.999
Peripheral neuropathy	4 (20.0)	6 (21.0)	0.014	0.999
Vomit	7 (35.0)	8 (29.0)	0.224	0.755
Fatigue	5 (25.0)	8 (29.0)	0.075	0.999
Anaemia	6 (30.0)	6 (21.0)	0.457	0.520
Anorexia	5 (25.0)	5 (18.0)	0.361	0.721
Rash	3 (15.0)	4 (14.0)	0.005	0.999
Thrombopenia	4 (20.0)	4 (14.0)	0.274	0.703
Abnormal liver function	5 (25.0)	4 (14.0)	0.879	0.460
Leukopenia	4 (20.0)	5 (18.0)	0.035	0.999

Table 3 Comparison of adverse reactions of immunotherapy in patients with advanced gastric cancer with liver metastasis and no liver metastasis grade 1-2, n (%)

Adverse reaction	Liver metastasis (n = 20)	No liver metastasis grade ≥ 3 (n = 28)	χ2	P value
All events related to treatment	5 (25.0)	7 (25.0)	0.001	0.999
Nausea	4 (20.0)	4 (14.0)	0.274	0.073
Diarrhea	2 (10.0)	3 (11.0)	0.006	0.999
Fever	2 (10.0)	4 (14.0)	0.196	0.999
Peripheral neuropathy	2 (10.0)	4 (14.0)	0.196	0.999
Vomit	5 (25.0)	5 (18.0)	0.361	0.721
Fatigue	4 (20.0)	5 (18.0)	0.035	0.999
Anaemia	1 (5.0)	4 (14.0)	1.078	0.385
Anorexia	2 (10.0)	4 (14.0)	0.196	0.999
Rash	1 (5.0)	2 (7.0)	0.091	0.999
Thrombopenia	2 (10.0)	1 (4.0)	0.823	0.563
Abnormal liver function	2 (10.0)	2 (7.0)	0.125	0.999
Leukopenia	3 (15.0)	4 (14.0)	0.005	0.999